<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Nephrol</journal-id><journal-id journal-id-type="pmc-domain-id">1150</journal-id><journal-id journal-id-type="pmc-domain">ijnephrol</journal-id><journal-id journal-id-type="publisher-id">IJN</journal-id><journal-title-group><journal-title>Indian Journal of Nephrology</journal-title></journal-title-group><issn pub-type="ppub">0971-4065</issn><issn pub-type="epub">1998-3662</issn><publisher><publisher-name>Scientific Scholar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8597799</article-id><article-id pub-id-type="pmcid-ver">PMC8597799.1</article-id><article-id pub-id-type="pmcaid">8597799</article-id><article-id pub-id-type="pmcaiid">8597799</article-id><article-id pub-id-type="pmid">34880551</article-id><article-id pub-id-type="doi">10.4103/ijn.IJN_73_19</article-id><article-id pub-id-type="publisher-id">IJN-31-425</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Continuous Ambulatory Peritoneal Dialysis Peritonitis Guidelines &#8211; Consensus Statement of Peritoneal Dialysis Society of India - 2020</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jeloka</surname><given-names initials="TK">Tarun K.</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abraham</surname><given-names initials="G">Georgi</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhalla</surname><given-names initials="AK">A. K.</given-names></name><xref rid="aff3" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balasubramaniam</surname><given-names initials="J">J.</given-names></name><xref rid="aff4" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dutta</surname><given-names initials="A">A.</given-names></name><xref rid="aff5" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gokulnath</surname><given-names initials=""/></name><xref rid="aff6" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gupta</surname><given-names initials="A">Amit</given-names></name><xref rid="aff7" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jha</surname><given-names initials="V">V.</given-names></name><xref rid="aff8" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khanna</surname><given-names initials="U">Umesh</given-names></name><xref rid="aff9" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahajan</surname><given-names initials="S">Sandeep</given-names></name><xref rid="aff10" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nayak</surname><given-names initials="KS">K. S.</given-names></name><xref rid="aff11" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prasad</surname><given-names initials="KN">K. N.</given-names></name><xref rid="aff12" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prasad</surname><given-names initials="N">Narayan</given-names></name><xref rid="aff7" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rathi</surname><given-names initials="M">Manish</given-names></name><xref rid="aff13" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Raju</surname><given-names initials="S">Sreebhushan</given-names></name><xref rid="aff14" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rohit</surname><given-names initials="A">Anusha</given-names></name><xref rid="aff15" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sahay</surname><given-names initials="M">Manisha</given-names></name><xref rid="aff16" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sampathkumar</surname><given-names initials="K">K.</given-names></name><xref rid="aff17" ref-type="aff">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sivakumar</surname><given-names initials="V">V.</given-names></name><xref rid="aff18" ref-type="aff">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Varughese</surname><given-names initials="S">Santosh</given-names></name><xref rid="aff19" ref-type="aff">18</xref></contrib></contrib-group><aff id="aff1">
<italic toggle="yes">Department of Nephrology, Aditya Birla Memorial Hospital, Pune, Maharashtra, India</italic>
</aff><aff id="aff2">
<label>1</label>
<italic toggle="yes">Department of Nephrology, Madras Medical Mission, Chennai, Tamil Nadu, India</italic>
</aff><aff id="aff3">
<label>2</label>
<italic toggle="yes">Department of Nephrology, Sir Ganga Ram Hospital, New Delhi, India</italic>
</aff><aff id="aff4">
<label>3</label>
<italic toggle="yes">Department of Nephrology, Kidney Care Centre, Tirunelveli, Tamil Nadu, India</italic>
</aff><aff id="aff5">
<label>4</label>
<italic toggle="yes">Department of Nephrology, Fortis Hospital and Kidney Institute, Kolkata, West Bengal, India</italic>
</aff><aff id="aff6">
<label>5</label>
<italic toggle="yes">Department of Nephrology, Apollo Hospital, Bengaluru, Karnataka, India</italic>
</aff><aff id="aff7">
<label>6</label>
<italic toggle="yes">Department of Nephrology, Sanjay Gandhi Post Graduate Institute, Lucknow, Uttar Pradesh, India</italic>
</aff><aff id="aff8">
<label>7</label>
<italic toggle="yes">The George Institute for Global Health, New Delhi, India</italic>
</aff><aff id="aff9">
<label>8</label>
<italic toggle="yes">Department of Nephrology, Lancelot Kidney and GI Centre, Mumbai, Maharashtra, India</italic>
</aff><aff id="aff10">
<label>9</label>
<italic toggle="yes">Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India</italic>
</aff><aff id="aff11">
<label>10</label>
<italic toggle="yes">Department of Nephrology, Virinchi Hospitals, Hyderabad, Telangana, India</italic>
</aff><aff id="aff12">
<label>11</label>
<italic toggle="yes">Department of Microbiology, Sanjay Gandhi Post Graduate Institute, Lucknow, Uttar Pradesh, India</italic>
</aff><aff id="aff13">
<label>12</label>
<italic toggle="yes">Department of Nephrology, Post Graduate Institute, Chandigarh, India</italic>
</aff><aff id="aff14">
<label>13</label>
<italic toggle="yes">Department of Nephrology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India</italic>
</aff><aff id="aff15">
<label>14</label>
<italic toggle="yes">Department of Microbiology, Madras Medical Mission, Chennai, Tamil Nadu, India</italic>
</aff><aff id="aff16">
<label>15</label>
<italic toggle="yes">Department of Nephrology, Osmania Hospital, Hyderabad, Telangana, India</italic>
</aff><aff id="aff17">
<label>16</label>
<italic toggle="yes">Department of Nephrology, Meenakshi Mission Hopsital and Research Centre, Madurai, Tamil Nadu, India</italic>
</aff><aff id="aff18">
<label>17</label>
<italic toggle="yes">Department of Nephrology, SriVenkateshwara Institute of Medical sciences, Tirupati, Andhra Pradesh, India</italic>
</aff><aff id="aff19">
<label>18</label>
<italic toggle="yes">Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India</italic>
</aff><author-notes><corresp id="cor1"><italic toggle="yes"><bold>Address for correspondence: </bold> Dr. Tarun K. Jeloka, Department of Nephrology, Aditya Birla Memorial Hospital, Thergaon, Chinchwad, Pune - 411 033, Maharashtra, India. E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tjeloka@yahoo.com">tjeloka@yahoo.com</email></italic></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2021</year></pub-date><pub-date pub-type="epub"><day>21</day><month>9</month><year>2021</year></pub-date><volume>31</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">393935</issue-id><fpage>425</fpage><lpage>434</lpage><history><date date-type="received"><day>07</day><month>4</month><year>2019</year></date><date date-type="rev-recd"><day>08</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>07</day><month>12</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-09 00:25:13.160"><day>09</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2021 Indian Journal of Nephrology</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IJN-31-425.pdf"/><abstract><p>Continuous ambulatory peritoneal dialysis (CAPD) related peritonitis is a major cause of technique failure, morbidity, and mortality in patients on CAPD. Its prevention and management is key to success of CAPD program. Due to variability in practice, microbiological trends and sensitivity towards antibiotics, there is a need for customized guidelines for management of CAPD related peritonitis (CAPDRP) in India. With this need, Peritoneal Dialysis Society of India (PDSI) organized a structured meeting to discuss various aspects of management of CAPDRP and formulated a consensus agreement which will help in management of patients with CAPDRP.</p></abstract><kwd-group><title>Keywords:</title><kwd><italic toggle="yes">Guidelines</italic></kwd><kwd><italic toggle="yes">peritoneal dialysis</italic></kwd><kwd><italic toggle="yes">peritoneal dialysis related peritonitis</italic></kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>It has been observed that the practice patterns of management of continuous ambulatory peritoneal dialysis related peritonitis (CAPDRP) is highly variable in India. Culture positive rates in India are also variable and mostly below the acceptable recommendations.[<xref rid="ref1" ref-type="bibr">1</xref>] We know that microbiological information is critical in optimal management of CAPDRP and is an important determinant of clinical outcome. A working group with representation from all zones of the country came together to formulate guidelines for treatment of CAPDRP after review of published literature and exhaustive debate on the subject.</p><p>This guideline for treatment of CAPDRP is intended to help practicing nephrologists in decision making while treating patients with CAPDRP. It does not define a standard of care of CAPDRP and the group acknowledges the variations in practice based on individual patients' needs, available resources, and limitations faced by clinicians. The working group also acknowledges the lack of high quality evidence on this issue from our country and hence the guideline is based on recommendations of International Society of Peritoneal dialysis (ISPD)[<xref rid="ref2" ref-type="bibr">2</xref>] with modifications suitable and applicable for India.</p><sec id="sec2-1"><title>Nomenclature and Description for rating guideline recommendations</title><p>We have used the terminology similar to Kidney Disease Improving Global Outcomes (KDIGO) guidelines [<xref rid="T1" ref-type="table">Table 1</xref>]. In view of paucity of literature from India, further subdivision into A, B, C and D is avoided.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Nomenclature of guideline statements</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Statement</th><th valign="top" align="left" rowspan="1" colspan="1">Implication for patients</th><th valign="top" align="left" rowspan="1" colspan="1">Implications for clinicians</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8220;We recommend&#8221;</td><td valign="top" align="left" rowspan="1" colspan="1">Most people in this situation would want the recommended course of action and only a small proportion would not</td><td valign="top" align="left" rowspan="1" colspan="1">Most patients should receive the recommended course of action</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8220;We suggest&#8221;</td><td valign="top" align="left" rowspan="1" colspan="1">The majority of people in this situation would want the suggested course of action, but many would not</td><td valign="top" align="left" rowspan="1" colspan="1">Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with their values and preferences</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec1-2"><title>Summary of Recommendations and Suggestions</title><p>Keys to successful PD program are dedicated team, appropriate training of patient and/or care giver, preventive measures for infection, appropriate culture methods, appropriate empiric antibiotics, preservation of peritoneum and periodic auditing. The selection of patient is also important, as utilization of PD as a last resort after failure of other modalities have compromised outcomes. CAPDRP is the most important and preventable cause of morbidity and mortality in peritoneal dialysis (PD) patients. High peritonitis rates can be a severe setback to any CAPD program.[<xref rid="ref3" ref-type="bibr">3</xref>]</p><p>This guideline is aimed to serve as a quick recap in the management of CAPDRP and is based on evidence-based recommendations of International Society of Peritoneal Dialysis guidelines for peritonitis, suggestions and expert consensus statements available in literature.</p><sec id="sec2-2"><title>Overview of the guidelines</title><sec id="sec3-1"><title>Prevention of CAPDRP</title><p>
<list list-type="bullet"><list-item><p>We recommend that systemic prophylactic antibiotic should be given prior to catheter insertion</p></list-item><list-item><p>We recommend that the disconnect system with 'flush before fill' bags should be used for continuous ambulatory peritoneal dialysis (CAPD)</p></list-item><list-item><p>We recommend that PD training should be conducted by a qualified nurse, preferably at the center, and reviewed for each patient by the nephrologist before certified to be complete</p></list-item><list-item><p>We suggest that prophylactic antibiotic should be given to all PD patients before any invasive procedure like dental, gynecological or intestinal</p></list-item><list-item><p>We recommend that topical antibiotic cream or ointment should be applied to the catheter exit site daily after bath</p></list-item><list-item><p>We recommend that catheter exit site or tunnel infections should be treated adequately so as to prevent subsequent peritonitis</p></list-item><list-item><p>We recommend that antifungal prophylaxis should be given whenever antibiotics are given to a CAPD patient to decrease fungal peritonitis.</p></list-item></list>
</p></sec><sec id="sec3-2"><title>Initial presentation and management of peritonitis</title><p><list list-type="bullet"><list-item><p>We recommend that peritonitis should be diagnosed when at least 2 of the 3 features are present:</p><p><list list-type="order"><list-item><p>Clinical features consistent with peritonitis like abdominal pain, cloudy dialysis effluent;</p></list-item><list-item><p>Dialysis effluent white cell count &gt;100/&#956;L (after a dwell time of at least 2 hours), with &gt;50% polymorphonuclear leucocytes; and</p></list-item><list-item><p>Positive dialysis effluent culture.</p></list-item></list>
</p></list-item><list-item><p>We recommend that all cloudy effluent should be considered peritonitis and treated accordingly till excluded.</p></list-item><list-item><p>We suggest sending the entire bag to the microbiology laboratory for analysis.</p></list-item><list-item><p>We recommend that PD effluent, when suspected of peritonitis, should be tested for total cell count, differential cell count, Gram stain, and culture.</p></list-item><list-item><p>We suggest initial testing for bacterial and fungal culture and if possible, in suspected, or in non-responding cases for mycobacterial cultures.</p></list-item></list>
</p></sec><sec id="sec3-3"><title>Empiric Antibiotic selection</title><p><list list-type="bullet"><list-item><p>We recommend that empiric antibiotic should be started as soon as possible when peritonitis is suspected, preferably after sending effluent for testing</p></list-item><list-item><p>We recommend that the choice of empiric antibiotic should be to cover both Gram positive and negative organism and better guided by local antibiogram</p></list-item><list-item><p>We recommend that Gram positive organism should be covered by Vancomycin and Gram negative by Piperacillin-Tazobactam or Aminoglycoside, unless local antibiogram suggest other antibiotics susceptibility</p></list-item><list-item><p>We recommend that preferred route of antibiotic administration should be intra-peritoneal (IP), unless there is evidence of severe systemic sepsis</p></list-item><list-item><p>We recommend that antibiotic should be deescalated once the antibiotic sensitivity pattern is available</p></list-item><list-item><p>We recommend that PD catheter should be removed in cases of refractory peritonitis, defined by failure of the PD effluent to clear up after 5 days of appropriate antibiotics</p></list-item><list-item><p>We suggest that peritonitis should be treated depending upon the bacteria isolated, at least for 2-3 weeks with appropriate antibiotic</p></list-item><list-item><p>We suggest that coagulase-negative Staphylococci should be treated for 2 weeks with appropriate antibiotics</p></list-item><list-item><p>We suggest Enterococcal peritonitis should be treated for 3 weeks. We also suggest adding an Aminoglycoside for severe infection. For Vancomycin Resistant Enterococci (VRE), we suggest 3 weeks of IP Ampicillin if it is sensitive or Linezolid, Daptomycin or Teicoplanin as per sensitivity, if ampicillin resistant</p></list-item><list-item><p>We suggest that Streptococcal peritonitis should be treated for 2 weeks</p></list-item><list-item><p>We suggest that Staphylococcus aureus peritonitis should be treated for 3 weeks</p></list-item><list-item><p>We suggest that Corynebacterial peritonitis should be treated for 3 weeks</p></list-item><list-item><p>We suggest that Pseudomonas peritonitis should be treated for 3 weeks with 2 susceptible antibiotics</p></list-item><list-item><p>We suggest that non-Pseudomonas Gram negative peritonitis should be treated for 3 weeks</p></list-item><list-item><p>We suggest that peritonitis associated with exit site and/or tunnel infection should be managed with catheter removal</p></list-item><list-item><p>We suggest that polymicrobial Gram negative peritonitis should be managed with surgical evaluation and antibiotics for 3 weeks</p></list-item><list-item><p>We suggest that culture negative peritonitis, if responding within 3 days, should be continued with same antibiotics, for 2 weeks. If no response, special culture techniques should be resorted to</p></list-item><list-item><p>We suggest that catheter should be removed for fungal peritonitis and anti-fungals to be given for 2 weeks</p></list-item><list-item><p>We suggest that tuberculous peritonitis should be treated appropriately with anti-Tuberculous drugs and catheter removal is suggested if there is no response.</p></list-item></list>
</p></sec><sec id="sec3-4"><title>Catheter removal and re-insertion</title><p><list list-type="bullet"><list-item><p>We recommend that PD catheter should be removed for refractory, relapsing and fungal peritonitis. Catheter should also be removed for non-tuberculous mycobacterial infections and individualized for tuberculous peritonitis</p></list-item><list-item><p>We suggest that re-insertion of catheter can be considered after 2-4 weeks of bacterial and 4-6 weeks of fungal peritonitis along with complete resolution of peritoneal symptoms</p></list-item><list-item><p>We recommend that each PD center should have a continuous quality improvement (CQI) program to reduce the rates of peritonitis.</p></list-item></list>
</p></sec></sec><sec id="sec2-3"><title>Guidelines for CAPD related peritonitis</title><sec id="sec3-5"><title>Prevention of PDRP</title><p>
<list list-type="bullet"><list-item><p>We recommend that one dose of systemic prophylactic antibiotic should be given just prior to catheter insertion.</p><p>Every center should determine the choice of antibiotic as per their spectrum of sensitivity towards skin and soft tissue antibiogram. Three randomized controlled trials (RCTs) showed reduction in early peritonitis with use of perioperative antibiotic.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] One trial showed no benefit.[<xref rid="ref7" ref-type="bibr">7</xref>] Systematic review of these trials shows benefit of prophylactic antibiotic.[<xref rid="ref8" ref-type="bibr">8</xref>]</p></list-item><list-item><p>We recommend that the disconnect system with 'flush before fill' bags should be used for continuous ambulatory peritoneal dialysis (CAPD).</p><p>The risk of developing peritonitis is reduced to 1/3<sup>rd</sup> with the use of Y system.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>] Also, there is no difference between the double bag or the Y system. There are conflicting results of comparison of peritonitis rates between CAPD and APD and peritonitis rate cannot be the basis of choice of any of these two modalities.</p></list-item><list-item><p>We recommend that PD training should be conducted by a qualified trainer, preferably at the center, and reviewed for each patient by the nephrologist before certified to be complete.</p><p>Training has great influence on incidence of peritonitis.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>] Though strong evidence is lacking on who should be the trainer,[<xref rid="ref22" ref-type="bibr">22</xref>] a well-trained nurse can dedicate time enough to train and monitor the exchange process. It is suggested to ensure proper training before making them independent, which can be done by the nephrologist (or other trained nurse, preferably not the same trainer). It is also suggested that retraining should be done periodically and after each episode of peritonitis.[<xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref19" ref-type="bibr">19</xref>]</p></list-item><list-item><p>We suggest that single dose prophylactic antibiotic should be given to all PD patients before any invasive procedure like dental, gynecological or intestinal.</p><p>Invasive procedure like colonoscopy has been shown to increase the risk of peritonitis.[<xref rid="ref23" ref-type="bibr">23</xref>] Prophylactic antibiotic before an invasive procedure except upper gastroscopy, reduces the risk of peritonitis.[<xref rid="ref24" ref-type="bibr">24</xref>] However, the choice of prophylactic antibiotic has not been studied and is left to the discretion of the local physician.</p></list-item><list-item><p>We recommend that topical antibiotic cream or ointment should be applied to the catheter exit site daily after bath.</p></list-item><list-item><p>We recommend that catheter exit site or tunnel infections should be treated adequately so as to prevent subsequent peritonitis.</p><p>There is an association between exit site infection (ESI) and subsequent peritonitis and hence appropriate management will reduce the risk of peritonitis.[<xref rid="ref25" ref-type="bibr">25</xref><xref rid="ref26" ref-type="bibr">26</xref><xref rid="ref27" ref-type="bibr">27</xref>] Though one of the systematic review did not show benefit of topical povidone-iodine in reducing peritonitis,[<xref rid="ref28" ref-type="bibr">28</xref>] another meta-analysis showed that topical mupirocin reduced rates of overall S. aureus infection by 72% and S. aureus peritonitis by 40%.[<xref rid="ref29" ref-type="bibr">29</xref>] Mupirocin resistance is of concern but is reported more with intermittent rather than daily use.[<xref rid="ref30" ref-type="bibr">30</xref><xref rid="ref31" ref-type="bibr">31</xref><xref rid="ref32" ref-type="bibr">32</xref><xref rid="ref33" ref-type="bibr">33</xref>] With extensive use of mupirocin ointment to reduce S aureus infections, Pseudomonas infection rates increased as a cause of catheter infections.[<xref rid="ref34" ref-type="bibr">34</xref>] An RCT showed topical gentamicin cream to the exit site was effective in reducing ESIs caused by Pseudomonas species as well as S aureus.[<xref rid="ref35" ref-type="bibr">35</xref>] However, other studies showed increased ESIs by Enterobacteriaceae, Pseudomonas species and non-tuberculous mycobacteria with use of gentamicin cream.[<xref rid="ref36" ref-type="bibr">36</xref><xref rid="ref37" ref-type="bibr">37</xref>] It is believed that topical gentamicin, however, is an acceptable alternative to mupirocin.</p><p>No definite anti-microbial guidelines are available for non-Tuberculous mycobacteria infections, but consensus is to treat with multiple antibiotics and remove the catheter.</p></list-item><list-item><p>We recommend that antifungal prophylaxis should be given whenever antibiotics are given to a PD patient to decrease fungal peritonitis. Antifungal prophylaxis should be continued for a week beyond antibiotics.</p><p>Fungal peritonitis is increased after antibiotic courses.[<xref rid="ref38" ref-type="bibr">38</xref><xref rid="ref39" ref-type="bibr">39</xref><xref rid="ref40" ref-type="bibr">40</xref>] Two randomized trials[<xref rid="ref41" ref-type="bibr">41</xref><xref rid="ref42" ref-type="bibr">42</xref>] and a systematic review[<xref rid="ref8" ref-type="bibr">8</xref>] showed benefits of prophylactic anti-fungals during antibiotic course in preventing subsequent fungal peritonitis.</p></list-item></list>
</p></sec><sec id="sec3-6"><title>Initial presentation and management of peritonitis</title><p>
<list list-type="bullet"><list-item><p>We recommend that peritonitis should be diagnosed when at least 2 of the 3 features are present:</p><p><list list-type="order"><list-item><p>Clinical features consistent with peritonitis like abdominal pain, cloudy dialysis effluent;</p></list-item><list-item><p>Dialysis effluent white cell count &gt;100/&#956;L (after a dwell time of at least 2 hours), with &gt;50% polymorphonuclear leucocytes; and</p></list-item><list-item><p>Positive dialysis effluent culture.</p></list-item></list>
</p></list-item><list-item><p>We recommend that all cloudy effluent should be considered peritonitis and treated accordingly till excluded.</p></list-item><list-item><p>We recommend that PD effluent, when suspected of peritonitis, should be tested for total and differential cell count, Gram stain, and culture.</p></list-item></list>
</p><p>Cloudy effluent should be treated as peritonitis unless proven otherwise. There are non infectious causes of cloudy effluent which should be considered in non classical presentations [<xref rid="T2" ref-type="table">Table 2</xref>].[<xref rid="ref43" ref-type="bibr">43</xref>] Patients presenting with abdominal pain should also be evaluated for peritonitis even when effluent is clear.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Differential diagnosis of cloudy effluent</p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Culture positive peritonitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Culture negative infectious peritonitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chemical peritonitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Calcium channel blockers</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Eosinophilia of the peritoneum</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hemoperitoneum</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Malignancy (rare)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chylous effluent (rare)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Specimen taken from &#8216;dry abdomen&#8217;</td></tr></tbody></table><table-wrap-foot><fn><p>Adapted and modified from Li PKT <italic toggle="yes">et al</italic>. Perit Dial Int 2016; 36(5): 481-508</p></fn></table-wrap-foot></table-wrap><p>When peritonitis is suspected, dialysis effluent should be drained, inspected for cloudiness, and sent for total and differential cell count, Gram stain, and culture.[<xref rid="ref44" ref-type="bibr">44</xref>] An effluent cell count with white blood cells (WBC) &gt;100/&#956;L (after a dwell time of at least 2 hours), with &gt;50% PMN, is highly suggestive of peritonitis.[<xref rid="ref45" ref-type="bibr">45</xref>] Appropriate antibiotic therapy (see below) should be initiated once the dialysis effluent specimens have been collected for analysis, without waiting for the results of laboratory testing. For patients on APD, percentage of PMN rather than the absolute WBC count should be used to diagnose peritonitis and a proportion above 50% PMN is strong evidence of peritonitis, even if the absolute WBC count is less than 100/&#956;L.[<xref rid="ref45" ref-type="bibr">45</xref>]</p><p>For patients in remote areas, they can keep the effluent bag refrigerated till they bring the bag for analysis and start intra peritoneal antibiotics as soon as possible. If possible, specimen should be processed within 6 hours of collection. Alternatively, they can send the effluent for analysis at local center or, if trained and available can inoculate into blood culture bottles, which should be provided to them. The inoculated culture bottles should be incubated at 37&#176;C.</p><p>Gram stain of PD effluent should be performed, preferably after centrifugation. Appropriate culture method is a key to positive results. After collection, 50 ml of effluent should be centrifuged at 3000 g for 15 minutes, followed by resuspension of the sediment in 3-5 ml supernatant and inoculation on solid culture media or standard blood culture media. If cultures remain negative after 3-5 days, PD effluent should be sent for repeat cell count, fungal and mycobacterial cultures.</p><p>A number of novel diagnostic techniques have been explored for the early diagnosis of peritonitis, including leukocyte esterase reagent strips, biomarker assays (matrix metalloproteinase-8 and -9, neutrophil gelatinase-associated lipocalin and procalcitonin), polymerase chain reaction (PCR) for bacterial-derived DNA fragments, 16S rRNA gene sequencing, matrix-assisted laser desorption ionization-time of flight (MALDI-TOF), and pathogen-specific &#8220;immune fingerprints&#8221;.[<xref rid="ref46" ref-type="bibr">46</xref><xref rid="ref47" ref-type="bibr">47</xref><xref rid="ref48" ref-type="bibr">48</xref><xref rid="ref49" ref-type="bibr">49</xref><xref rid="ref50" ref-type="bibr">50</xref><xref rid="ref51" ref-type="bibr">51</xref><xref rid="ref52" ref-type="bibr">52</xref><xref rid="ref53" ref-type="bibr">53</xref><xref rid="ref54" ref-type="bibr">54</xref><xref rid="ref55" ref-type="bibr">55</xref><xref rid="ref56" ref-type="bibr">56</xref><xref rid="ref57" ref-type="bibr">57</xref><xref rid="ref58" ref-type="bibr">58</xref>] However, none of them has been proved to be superior to conventional culture techniques.</p></sec><sec id="sec3-7"><title>Empiric Antibiotic selection</title><p>
<list list-type="bullet"><list-item><p>We recommend that empiric antibiotic should be started as soon as possible when peritonitis is suspected, preferably after sending effluent for testing.</p></list-item><list-item><p>We recommend that the choice of empiric antibiotic should be to cover both Gram positive and negative organism and better guided by local antibiogram.</p></list-item><list-item><p>We recommend that Gram positive organism should be covered by Vancomycin and Gram negative by Piperacillin-Tazobactam or Aminoglycosides unless local antibiogram suggest other susceptibility.</p><p>In the recent data analysis, gram-positive organisms are more commonly encountered across the country but almost close to gram-negative organisms.[<xref rid="ref2" ref-type="bibr">2</xref>] However, center wise difference have also been noted. It is suggested to start with antibiotics covering for both positive and negative organisms. In a meta-analysis,[<xref rid="ref55" ref-type="bibr">55</xref>] the combination of a glycopeptide (vancomycin or teicoplanin) and ceftazidime was superior to other regimens. However, the sensitivity pattern across all zones in India suggest resistance towards cephalosporins and better sensitivity to piperacillin-tazobactam. Cefepime or imipenem/cilastatin can be used as monotherapy. Once the culture results are available, antibiotics can be adjusted and deescalated to avoid future antibiotic resistance.</p></list-item><list-item><p>We recommend that preferred route of antibiotic administration should be intra-peritoneal (IP), unless there is evidence of severe systemic sepsis.</p></list-item><list-item><p>We recommend that antibiotic should be deescalated once the antibiotic sensitivity pattern is available.</p><p>Intraperitoneal dosing results in high IP drug levels and is preferable to IV administration. Intraperitoneal antibiotics can be given as continuous (in each exchange) or intermittent dosing (once daily).[<xref rid="ref59" ref-type="bibr">59</xref><xref rid="ref60" ref-type="bibr">60</xref><xref rid="ref61" ref-type="bibr">61</xref><xref rid="ref62" ref-type="bibr">62</xref><xref rid="ref63" ref-type="bibr">63</xref><xref rid="ref64" ref-type="bibr">64</xref>] In intermittent dosing, the antibiotic-containing dialysis solution must be allowed to dwell for at least six hours to allow adequate absorption. The role of monitoring serum vancomycin levels is controversial.[<xref rid="ref65" ref-type="bibr">65</xref><xref rid="ref66" ref-type="bibr">66</xref>] In general, a dosing interval of every 4 to 5 days would keep serum trough levels above 15 &#956;g/mL, but there is substantial inter-individual variability.[<xref rid="ref65" ref-type="bibr">65</xref><xref rid="ref67" ref-type="bibr">67</xref>] Re-dosing is probably appropriate when serum vancomycin levels are below 15 &#956;g/mL.[<xref rid="ref67" ref-type="bibr">67</xref><xref rid="ref68" ref-type="bibr">68</xref><xref rid="ref69" ref-type="bibr">69</xref>] There is no firm evidence that monitoring aminoglycoside levels mitigates toxicity risk or enhances efficacy.[<xref rid="ref69" ref-type="bibr">69</xref>]</p><p>Antibiotic dosing in APD is of concern because of rapid exchanges. However, intermittent dosing given at long day dwell is effective. Alternatively, if possible, patients may switch to CAPD till completion of the treatment. The recommended dosage of antibiotics for the treatment of PD related peritonitis is summarized in [Tables <xref rid="T3" ref-type="table">3</xref> and <xref rid="T4" ref-type="table">4</xref>].[<xref rid="ref2" ref-type="bibr">2</xref>]</p></list-item><list-item><p>We recommend that PD catheter should be removed in cases of refractory peritonitis.</p><p>Refractory peritonitis is defined as failure of the PD effluent to clear up after 5 days of appropriate antibiotics. If there is failure to respond to empiric antibiotic in culture negative or to susceptible antibiotic in culture positive peritonitis in 3 days, a trial of higher / susceptible antibiotic is recommended for another 2 days before labelling it as refractory. Catheter removal is indicated in cases of refractory peritonitis. Delay in catheter removal leads to extended hospital stay, peritoneal membrane damage, increased risk of fungal peritonitis and excessive mortality.[<xref rid="ref70" ref-type="bibr">70</xref>] Catheter should also be removed if patient's condition is deteriorating.</p></list-item><list-item><p>We suggest that coagulase-negative Staphylococci (CONS) should be treated for 2 weeks with appropriate antibiotics.</p><p>CONS is mostly due to touch contamination. Intraperitoneal vancomycin or cephalosporins can be advised for 2 weeks. Relapsing CONS peritonitis suggests colonization and bio-film formation, when catheter removal may be considered.</p></list-item><list-item><p>We suggest Enterococcal peritonitis should be treated for 3 weeks. We also suggest adding an Aminoglycoside for severe infection. For Vancomycin Resistant Enterococci (VRE), we suggest 3 weeks of IP Ampicillin if it is sensitive or Linezolid, Daptomycin or Teicoplanin as per sensitivity, if ampicillin resistant.</p><p>Enterococci infection suggests intra-abdominal source of infection. Identification of species is important as many are resistant to penicillins and carbapenems.</p></list-item><list-item><p>We suggest that Streptococcal peritonitis should be treated for 2 weeks.</p><p>Streptococci frequently originate from the mouth,[<xref rid="ref71" ref-type="bibr">71</xref>] although S bovis comes from the colon.[<xref rid="ref72" ref-type="bibr">72</xref>] Streptococcus viridans are more likely to be refractory.</p></list-item><list-item><p>We suggest that Staphylococcus aureus peritonitis should be treated for 3 weeks.</p><p>S aureus is often secondary to touch contamination, exit site or tunnel infection. Data suggests 3 weeks treatment[<xref rid="ref73" ref-type="bibr">73</xref><xref rid="ref74" ref-type="bibr">74</xref>] with appropriate antibiotic. Concomitant exit site or tunnel infection may need catheter removal.</p></list-item><list-item><p>We suggest that Corynebacterial peritonitis should be treated for 3 weeks.</p></list-item><list-item><p>We suggest that Pseudomonas peritonitis should be treated for 3 weeks with 2 susceptible antibiotics.</p><p>Pseudomonas peritonitis is associated with higher rates of hospitalizations, catheter removal and transfer to hemodialysis. The outcome is reported to be better with 2 anti-pseudomonal antibiotics.[<xref rid="ref75" ref-type="bibr">75</xref>]</p></list-item><list-item><p>We suggest that non Pseudomonas Gram negative peritonitis should be treated for 3 weeks.</p><p>The SPICE organisms (Serratia, Pseudomonas, indole positive organisms like Proteus and Providentia, Citrobacter, and Enterobacter) have amp C beta lactamases which can inactivate cephalosporins and have an increased risk of relapse. There are observational studies which shows treatment with 2 antibiotics for 3 to 4 weeks have better results.[<xref rid="ref76" ref-type="bibr">76</xref>]</p></list-item><list-item><p>We suggest that peritonitis associated with exit site and/or tunnel infection should be managed with catheter removal.</p><p>It is believed that peritonitis associated with ESI or tunnel infection is because of peri-catheter translocation of bacteria. The outcome of such infections are poor and catheter removal with appropriate antibiotic helps in decreasing the morbidity.</p></list-item><list-item><p>We suggest that polymicrobial Gram negative peritonitis should be managed with surgical evaluation and antibiotics for 3 weeks.</p><p>When multiple enteric organisms are isolated, intra-abdominal pathology is a possibility and should be evaluated. The choice of antibiotic becomes metronidazole with vancomycin with cephalosporin or aminoglycoside. Carbapenems or piperacillin/tazobactam are an alternative.</p></list-item><list-item><p>We suggest that culture negative peritonitis, if responding within 3 days, should be treated with same antibiotics for 2 weeks. Early response usually is due to CONS, but several centers have reported equal or higher incidence of gram negative organisms and the consensus was to continue both the empiric antibiotics for 2 weeks. If no response within 5 days, special culture techniques should be resorted to.</p><p>Inappropriate culture technique is the most common cause of 'culture negative' peritonitis. Recent antibiotic usage also leads to culture negative peritonitis. Predominantly, these are due to gram positive organisms and hence, if responded within 3 days, should be managed for 2 weeks.[<xref rid="ref77" ref-type="bibr">77</xref><xref rid="ref78" ref-type="bibr">78</xref><xref rid="ref79" ref-type="bibr">79</xref>]</p></list-item><list-item><p>We suggest that catheter should be removed for fungal peritonitis and anti-fungals to be given for 2 weeks.</p><p>Fungal peritonitis is associated with higher rates of hospitalization, transfer to hemodialysis, and death.[<xref rid="ref80" ref-type="bibr">80</xref><xref rid="ref81" ref-type="bibr">81</xref><xref rid="ref82" ref-type="bibr">82</xref><xref rid="ref83" ref-type="bibr">83</xref>] Catheter removal is suggested once diagnosis is confirmed to reduce mortality and preserve the peritoneum. Anti-fungal agents are continued for 2 weeks after catheter removal. The choice of anti-fungals are a combination of amphotericin B and flucytosine. However, IP amphotericin may cause chemical peritonitis and IV has poor peritoneal bioavailability. Flucytosine is not widely available. Other agents include fluconazole (for Candida and cryptococcus), echinocandins (for Aspergillus and non-albicans Candida), posconazole, and voriconazole (for filamentous fungi).</p></list-item><list-item><p>We suggest that Tuberculous peritonitis should be treated appropriately with anti-tuberculous drugs and catheter removal is considered if there is no response.</p></list-item></list>
</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Intraperitoneal Antibiotic Dosing Recommendations for Treatment of Peritonitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Intermittent (1 exchange daily)</th><th valign="top" align="left" rowspan="1" colspan="1">Continuous (all exchanges)</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Aminoglycosides</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Amikacin</td><td valign="top" align="left" rowspan="1" colspan="1">2 mg/kg daily</td><td valign="top" align="left" rowspan="1" colspan="1">LD 25 mg/L, MD 12 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gentamicin</td><td valign="top" align="left" rowspan="1" colspan="1">0.6 mg/kg daily</td><td valign="top" align="left" rowspan="1" colspan="1">LD 8 mg/L, MD 4 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Netilmicin</td><td valign="top" align="left" rowspan="1" colspan="1">0.6 mg/kg daily</td><td valign="top" align="left" rowspan="1" colspan="1">MD 10 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tobramycin</td><td valign="top" align="left" rowspan="1" colspan="1">0.6 mg/kg daily</td><td valign="top" align="left" rowspan="1" colspan="1">LD 3 mg/kg, MD 0.3 mg/kg</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cephalosporins</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cefazolin</td><td valign="top" align="left" rowspan="1" colspan="1">15-20 mg/kg daily</td><td valign="top" align="left" rowspan="1" colspan="1">LD 500 mg/L, MD 125 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cefepime</td><td valign="top" align="left" rowspan="1" colspan="1">1,000 mg daily</td><td valign="top" align="left" rowspan="1" colspan="1">LD 250-500 mg/L, MD 100-125 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cefoperazone</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">LD 500 mg/L, MD 62.5-125 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cefotaxime</td><td valign="top" align="left" rowspan="1" colspan="1">500-1,000 mg daily</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ceftazidime</td><td valign="top" align="left" rowspan="1" colspan="1">1,000-1,500 mg daily</td><td valign="top" align="left" rowspan="1" colspan="1">LD 500 mg/L, MD 125 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ceftriaxone</td><td valign="top" align="left" rowspan="1" colspan="1">1,000 mg daily</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Penicillins</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Penicillin G</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">LD 50,000 unit/L, MD 25,000 unit/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Amoxicillin</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">MD 150 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ampicillin</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">MD 125 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ampicillin/Sulbactam</td><td valign="top" align="left" rowspan="1" colspan="1">2 gm/1 gm every 12 hours</td><td valign="top" align="left" rowspan="1" colspan="1">LD 750-100 mg/L, MD 100 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Piperacillin/Tazobactam</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">LD 4 gm/0.5 gm, MD 1 gm/0.125 gm</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Others</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aztreonam</td><td valign="top" align="left" rowspan="1" colspan="1">2 gm daily</td><td valign="top" align="left" rowspan="1" colspan="1">LD 1,000 mg/L, MD 250 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ciprofloxacin</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">MD 50 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Clindamycin</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">MD 600 mg/bag</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Daptomycin</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">LD 100 mg/L, MD 20 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Imipenem/Cilastatin</td><td valign="top" align="left" rowspan="1" colspan="1">500 mg in alternate exchange</td><td valign="top" align="left" rowspan="1" colspan="1">LD 250 mg/L, MD 50 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ofloxacin</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">LD 200 mg, MD 25 mg/L</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Polymyxin B</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td><td valign="top" align="left" rowspan="1" colspan="1">MD 300,000 unit (30 mg)/bag</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Meropenem</td><td valign="top" align="left" rowspan="1" colspan="1">1 gm daily</td><td valign="top" align="left" rowspan="1" colspan="1">125 mg/L (case report)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Teicoplanin</td><td valign="top" align="left" rowspan="1" colspan="1">15 mg/kg every 5 days</td><td valign="top" align="left" rowspan="1" colspan="1">LD 400 mg/bag, MD 20 mg/bag</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vancomycin</td><td valign="top" align="left" rowspan="1" colspan="1">15-30 mg/kg every 5-7 days (Supplement doses for APD patients)</td><td valign="top" align="left" rowspan="1" colspan="1">LD 30 mg/kg, MD 1.5 mg/kg/bag</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Antifungals</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fluconazole</td><td valign="top" align="left" rowspan="1" colspan="1">IP 200 mg every 24 to 48 hours</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Voriconazole</td><td valign="top" align="left" rowspan="1" colspan="1">IP 2.5 mg/kg daily</td><td valign="top" align="left" rowspan="1" colspan="1">no data</td></tr></tbody></table><table-wrap-foot><fn><p>LD = Loading dose in mg; MD = Maintenance dose in mg; IP = Intraperitoneal; APD = Automated peritoneal dialysis. Adapted and modified from Li PKT <italic toggle="yes">et al</italic>. Perit Dial Int 2016; 36(5): 481-508</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Systemic Antibiotic Dosing Recommendations for Treatment of Peritonitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Drug</th><th valign="top" align="left" rowspan="1" colspan="1">Dosing</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Anti-bacterials</th><th valign="top" align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Ciprofloxacin</td><td valign="top" align="left" rowspan="1" colspan="1">Oral 250 mg BD (500 mg BD, if residual renal function &gt; 5 ml/min)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Colistin</td><td valign="top" align="left" rowspan="1" colspan="1">IV 300 mg loading, then 150-200 mg daily (expressed as Colistin Base Activity, CBA)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ertapenem</td><td valign="top" align="left" rowspan="1" colspan="1">IV 500 mg daily</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Levofloxacin</td><td valign="top" align="left" rowspan="1" colspan="1">Oral 250 mg daily</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Linezolid</td><td valign="top" align="left" rowspan="1" colspan="1">IV or oral 600 mg BD</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moxifloxacin</td><td valign="top" align="left" rowspan="1" colspan="1">Oral 400 mg daily</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rifampicin</td><td valign="top" align="left" rowspan="1" colspan="1">450 mg daily for BW &lt;50;600 mg daily for BW &#8805;50 kg</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Trimethoprim/Sulfamethoxazole</td><td valign="top" align="left" rowspan="1" colspan="1">Oral 160 mg / 800 mg BD</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Anti-fungals</th><th valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Amphotericin</td><td valign="top" align="left" rowspan="1" colspan="1">IV test dose 1 mg; starting dose 0.1 mg/kg/day over 6 hours; increased to target dose 0.75 1.0 mg/kg/day over 4 days</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Caspofungin</td><td valign="top" align="left" rowspan="1" colspan="1">IV 70 mg loading, then 50 mg daily</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fluconazole</td><td valign="top" align="left" rowspan="1" colspan="1">Oral 200 mg loading, then 50-100 mg daily</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Posaconazole</td><td valign="top" align="left" rowspan="1" colspan="1">IV 400 mg every 12 hours</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Voriconazole</td><td valign="top" align="left" rowspan="1" colspan="1">Oral 200 mg every 12 hours</td></tr></tbody></table><table-wrap-foot><fn><p>BD = Twice a day; IV = Intravenous; BW = Body weight. Adapted and modified from Li PKT <italic toggle="yes">et al</italic>. Perit Dial Int 2016; 36(5): 481-508</p></fn></table-wrap-foot></table-wrap><p>Patient with refractory or relapsing peritonitis with negative bacterial cultures should be suspected of tuberculous peritonitis. Routine testing for tuberculosis like Ziehl Neelsen stain or conventional culture are not sufficiently sensitive. Culture in fluid medium like MGIT or BactAlert or mycobacterial DNA PCR (Gene Xpert) can be better in diagnosing tuberculous peritonitis. Laproscopic peritoneal or omental biopsy can be diagnostic in suspicious cases.[<xref rid="ref84" ref-type="bibr">84</xref>] Catheter removal is required only if patient is sick or is non-responding to drug therapy.</p></sec><sec id="sec3-8"><title>Catheter removal and re-insertion</title><p>
<list list-type="bullet"><list-item><p>We recommend that PD catheter should be removed for refractory, relapsing and fungal peritonitis. Catheter should also be removed for non-tuberculous mycobacterial infections and individualized for tuberculous peritonitis.</p></list-item><list-item><p>We suggest that re-insertion of catheter can be considered after 2-4 weeks of bacterial and 4-6 weeks of fungal peritonitis along with complete resolution of peritoneal symptoms.</p><p>There is enough evidence of poor outcome while salvaging catheters in refractory, relapsing and fungal peritonitis. However, for non-tuberculous mycobacterial infections, there are case reports and series which suggest catheter removal[<xref rid="ref85" ref-type="bibr">85</xref>] along with multi-agent antibiotic therapy.</p></list-item><list-item><p>We recommend that each PD center should have a continuous quality improvement (CQI) program to reduce the rates of peritonitis. Satellite centers may strengthen the patient management and the PD program.</p><p>Monitoring of peritonitis rates and outcomes annually gives an insight on culture negative peritonitis rates, incidence of peritonitis and its outcome. This may reveal the cause of failure of cultures and measures to improve culture positive rates. Incidence rates may also help establish the lacunae in training or re-training needs of patients. Comparing the incidence and outcome of peritonitis and discussions with other centers may help improving the overall outcome of PD patients.</p></list-item></list>
</p></sec></sec><sec id="sec2-4"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" id="sec2-5"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>We are grateful to Dr. S. K. Agarwal, who has given valuable inputs and guidance in the preparation and finalization of this guideline.</p></ack><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>G</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>KN</given-names></name><name name-style="western"><surname>Rohit</surname><given-names>A</given-names></name><name name-style="western"><surname>Billa</surname><given-names>V</given-names></name><name name-style="western"><surname>Chakravarthy</surname><given-names>R</given-names></name><etal/></person-group><article-title>Microbiology, clinical spectrum and outcome of peritonitis in patients undergoing peritoneal dialysis in India: Results from a multicentric, observational study</article-title><source>J Trop Dis</source><year>2016</year><volume>4</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmm.IJMM_17_392</pub-id><pub-id pub-id-type="pmid">29405139</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>PK</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>CC</given-names></name><name name-style="western"><surname>Piraino</surname><given-names>B</given-names></name><name name-style="western"><surname>de Arteaga</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>AE</given-names></name><etal/></person-group><article-title>ISPD peritonitis recommendations: 2016 update on prevention and treatment</article-title><source>Perit Dial Int</source><year>2016</year><volume>36</volume><fpage>481</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">27282851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2016.00078</pub-id><pub-id pub-id-type="pmcid">PMC5033625</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>G</given-names></name><name name-style="western"><surname>Thiagarajan</surname><given-names>T</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>M</given-names></name></person-group><article-title>Prevention of peritoneal dialysis related infections as a means to prevent dropout</article-title><source>Indian J Nephrol</source><year>2005</year><volume>15</volume><fpage>S10</fpage><lpage>3</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wikdahl</surname><given-names>AM</given-names></name><name name-style="western"><surname>Engman</surname><given-names>U</given-names></name><name name-style="western"><surname>Stegmayr</surname><given-names>BG</given-names></name><name name-style="western"><surname>S&#246;renssen</surname><given-names>JG</given-names></name></person-group><article-title>One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion</article-title><source>Nephrol Dial Transplant</source><year>1997</year><volume>12</volume><fpage>157</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9027792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/12.1.157</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennet-Jones</surname><given-names>DN</given-names></name><name name-style="western"><surname>Martin</surname><given-names>JB</given-names></name><name name-style="western"><surname>Barratt</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Naish</surname><given-names>PF</given-names></name><name name-style="western"><surname>Aber</surname><given-names>GM</given-names></name></person-group><article-title>Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD</article-title><source>Adv Perit Dial</source><year>1988</year><volume>4</volume><fpage>147</fpage><lpage>50</lpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gadallah</surname><given-names>MF</given-names></name><name name-style="western"><surname>Ramdeen</surname><given-names>G</given-names></name><name name-style="western"><surname>Mignone</surname><given-names>J</given-names></name><name name-style="western"><surname>Patel</surname><given-names>D</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>L</given-names></name><name name-style="western"><surname>Tatro</surname><given-names>S</given-names></name></person-group><article-title>Role of preoperative antibiotic prophylaxis in preventing postoperative perito-nitis in newly placed peritoneal dialysis catheters</article-title><source>Am J Kidney Dis</source><year>2000</year><volume>36</volume><fpage>1014</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11054359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/ajkd.2000.19104</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lye</surname><given-names>WC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Tan</surname><given-names>CC</given-names></name></person-group><article-title>Prophylactic antibiotics in the insertion of Tenck-hoff catheters</article-title><source>Scand J Urol Nephrol</source><year>1992</year><volume>26</volume><fpage>177</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">1626207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00365599.1992.11690450</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strippoli</surname><given-names>GFM</given-names></name><name name-style="western"><surname>Tong</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D</given-names></name><name name-style="western"><surname>Schena</surname><given-names>FP</given-names></name><name name-style="western"><surname>Craig</surname><given-names>JC</given-names></name></person-group><article-title>Antimicrobial agents to prevent peritonitis in peritoneal dialysis: A systematic review of randomized controlled trials</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>44</volume><fpage>591</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">15384009</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strippoli</surname><given-names>GF</given-names></name><name name-style="western"><surname>Tong</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D</given-names></name><name name-style="western"><surname>Schena</surname><given-names>FP</given-names></name><name name-style="western"><surname>Craig</surname><given-names>JC</given-names></name></person-group><article-title>Catheter-related interventions to prevent peritonitis in peritoneal dialysis: A system-atic review of randomized, controlled trials</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><fpage>2735</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15466279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ASN.0000141463.95561.79</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>C</given-names></name><name name-style="western"><surname>Cody</surname><given-names>JD</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I</given-names></name><name name-style="western"><surname>Rabindranath</surname><given-names>KS</given-names></name><name name-style="western"><surname>Vale</surname><given-names>L</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>SA</given-names></name></person-group><article-title>Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage kidney disease</article-title><source>Cochrane Database Syst Rev</source><year>2014</year><volume>8</volume><fpage>CD003078</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD003078.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6457793</pub-id><pub-id pub-id-type="pmid">25117423</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figueiredo</surname><given-names>AE</given-names></name><name name-style="western"><surname>Bernardini</surname><given-names>J</given-names></name><name name-style="western"><surname>Bowes</surname><given-names>E</given-names></name><name name-style="western"><surname>Hiramatsu</surname><given-names>M</given-names></name><name name-style="western"><surname>Price</surname><given-names>V</given-names></name><name name-style="western"><surname>Su</surname><given-names>C</given-names></name><etal/></person-group><article-title>ISPD guideline / recommendations: A syllabus for teaching peritoneal dialysis to patients and caregivers</article-title><source>Perit Dial Int</source><year>2016</year><comment>doi: 10.3747/pdi.2015.00277 (Epub ahead of print)</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2015.00277</pub-id><pub-id pub-id-type="pmcid">PMC5174866</pub-id><pub-id pub-id-type="pmid">26917664</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardini</surname><given-names>J</given-names></name><name name-style="western"><surname>Price</surname><given-names>V</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>A</given-names></name></person-group><article-title>Peritoneal dialysis patient training, 2006</article-title><source>Perit Dial Int</source><year>2006</year><volume>26</volume><fpage>625</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17047225</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bender</surname><given-names>FH</given-names></name><name name-style="western"><surname>Bernardini</surname><given-names>J</given-names></name><name name-style="western"><surname>Piraino</surname><given-names>B</given-names></name></person-group><article-title>Prevention of infectious complications in peritoneal dialysis: Best demonstrated practices</article-title><source>Kidney Int Suppl</source><year>2006</year><volume>103</volume><fpage>S44</fpage><lpage>54</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ki.5001915</pub-id><pub-id pub-id-type="pmid">17080111</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>G</given-names></name><name name-style="western"><surname>Bogan</surname><given-names>A</given-names></name><name name-style="western"><surname>Dreis</surname><given-names>S</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>A</given-names></name><name name-style="western"><surname>Greene</surname><given-names>S</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>K</given-names></name><etal/></person-group><article-title>New directions in peritoneal dialysis patient training</article-title><source>Nephrol Nurs J</source><year>2004</year><volume>31</volume><fpage>149</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15114797</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holloway</surname><given-names>M</given-names></name><name name-style="western"><surname>Mujais</surname><given-names>S</given-names></name><name name-style="western"><surname>Kandert</surname><given-names>M</given-names></name><name name-style="western"><surname>Warady</surname><given-names>BA</given-names></name></person-group><article-title>Pediatric peritoneal dialysis training: Characteristics and impact on peritonitis rates</article-title><source>Perit Dial Int</source><year>2001</year><volume>21</volume><fpage>401</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11587405</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>KM</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>CC</given-names></name><name name-style="western"><surname>Law</surname><given-names>MC</given-names></name><name name-style="western"><surname>Fung</surname><given-names>JS</given-names></name><name name-style="western"><surname>Li</surname><given-names>PK</given-names></name></person-group><article-title>Influence of peritoneal dialysis training nurses' experience on peritonitis rates</article-title><source>Clin J Am Soc Nephrol</source><year>2007</year><volume>2</volume><fpage>647</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17699477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.03981206</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>R</given-names></name><name name-style="western"><surname>Manili</surname><given-names>L</given-names></name><name name-style="western"><surname>Tiraboschi</surname><given-names>G</given-names></name><name name-style="western"><surname>Amar</surname><given-names>K</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>M</given-names></name><name name-style="western"><surname>Alberghini</surname><given-names>E</given-names></name><etal/></person-group><article-title>Patient re-training in peritoneal dialysis: Why and when it is needed</article-title><source>Kidney Int Suppl</source><year>2006</year><volume>103</volume><fpage>S127</fpage><lpage>32</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ki.5001929</pub-id><pub-id pub-id-type="pmid">17080104</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballerini</surname><given-names>L</given-names></name><name name-style="western"><surname>Paris</surname><given-names>V</given-names></name></person-group><article-title>Nosogogy: When the learner is a patient with chronic kidney failure</article-title><source>Kid Int</source><year>2006</year><volume>70</volume><fpage>S122</fpage><lpage>6</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ki.5001928</pub-id><pub-id pub-id-type="pmid">17080103</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arndt</surname><given-names>J</given-names></name></person-group><article-title>From compliance and false memory</article-title><source>J Exp Psych</source><year>2010</year><volume>36</volume><fpage>66</fpage><lpage>9</lpage></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bordin</surname><given-names>G</given-names></name><name name-style="western"><surname>Cassati</surname><given-names>M</given-names></name><name name-style="western"><surname>Sicolo</surname><given-names>N</given-names></name><name name-style="western"><surname>Zuccherato</surname><given-names>N</given-names></name><name name-style="western"><surname>Eduati</surname><given-names>V</given-names></name></person-group><article-title>Patient education in peritoneal dialysis: An observational study in Italy</article-title><source>J Ren Care</source><year>2007</year><volume>33</volume><fpage>165</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">18298034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-6686.2007.tb00067.x</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Impact of the bag exchange procedure on risk of peri-tonitis</article-title><source>Perit Dial Int</source><year>2010</year><volume>30</volume><fpage>440</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20378843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2009.00117</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>CM</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DW</given-names></name></person-group><article-title>Focus on peritoneal dialysis training: Working to decrease peritonitis rates</article-title><source>Nephrol Dial Transplant</source><year>2016</year><volume>31</volume><fpage>214</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">26908816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfu403</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yip</surname><given-names>T</given-names></name><name name-style="western"><surname>Tse</surname><given-names>KC</given-names></name><name name-style="western"><surname>Lam</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>SW</given-names></name><name name-style="western"><surname>Lui</surname><given-names>SL</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Risks and outcomes of peritonitis after flexible colonoscopy in CAPD patients</article-title><source>Perit Dial Int</source><year>2007</year><volume>27</volume><fpage>560</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">17704448</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>HH</given-names></name><name name-style="western"><surname>Li</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Weng</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>MY</given-names></name><etal/></person-group><article-title>Prophylactic antibiotics for endoscopy-associated peritonitis in peritoneal dialysis patients</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e71532</fpage><pub-id pub-id-type="pmid">23936514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0071532</pub-id><pub-id pub-id-type="pmcid">PMC3731321</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Diepen</surname><given-names>AT</given-names></name><name name-style="western"><surname>Tomlinson</surname><given-names>GA</given-names></name><name name-style="western"><surname>Jassal</surname><given-names>SV</given-names></name></person-group><article-title>The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients</article-title><source>Clin J Am Soc Nephrol</source><year>2012</year><volume>7</volume><fpage>1266</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">22745277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.00980112</pub-id><pub-id pub-id-type="pmcid">PMC3408122</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Diepen</surname><given-names>AT</given-names></name><name name-style="western"><surname>Jassal</surname><given-names>SV</given-names></name></person-group><article-title>A qualitative systematic review of the literature supporting a causal relationship between exit-site infection and subse-quent peritonitis in patients with end-stage renal disease treated with peritoneal dialysis</article-title><source>Perit Dial Int</source><year>2013</year><volume>33</volume><fpage>604</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">24335122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2012.00082</pub-id><pub-id pub-id-type="pmcid">PMC3862089</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lloyd</surname><given-names>A</given-names></name><name name-style="western"><surname>Tangri</surname><given-names>N</given-names></name><name name-style="western"><surname>Shafer</surname><given-names>LA</given-names></name><name name-style="western"><surname>Rigatto</surname><given-names>C</given-names></name><name name-style="western"><surname>Perl</surname><given-names>J</given-names></name><name name-style="western"><surname>Komenda</surname><given-names>P</given-names></name><etal/></person-group><article-title>The risk of peritonitis after an exit site infection: A time-matched, case-control study</article-title><source>Nephrol Dial Transplant</source><year>2013</year><volume>28</volume><fpage>1915</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">23382265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gft002</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strippoli</surname><given-names>GF</given-names></name><name name-style="western"><surname>Tong</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D</given-names></name><name name-style="western"><surname>Schena</surname><given-names>FP</given-names></name><name name-style="western"><surname>Craig</surname><given-names>JC</given-names></name></person-group><article-title>Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients</article-title><source>Cochrane Database Syst Rev</source><year>2004</year><volume>4</volume><fpage>CD004679</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD004679.pub2</pub-id><pub-id pub-id-type="pmid">15495124</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Tu</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name></person-group><article-title>Mupirocin for preventing exit-site infection and perito-nitis in patients undergoing peritoneal dialysis</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><fpage>587</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">19679557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfp411</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobbedeez</surname><given-names>T</given-names></name><name name-style="western"><surname>Gardam</surname><given-names>M</given-names></name><name name-style="western"><surname>Dedier</surname><given-names>H</given-names></name><name name-style="western"><surname>Burdzy</surname><given-names>D</given-names></name><name name-style="western"><surname>Chu</surname><given-names>M</given-names></name><name name-style="western"><surname>Izatt</surname><given-names>S</given-names></name><etal/></person-group><article-title>Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resis-tance: Still low after 7 years</article-title><source>Nephrol Dial Transplant</source><year>2004</year><volume>19</volume><fpage>3140</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15466881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfh494</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Fontan</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosales</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodriguez-Carmona</surname><given-names>A</given-names></name><name name-style="western"><surname>Falcon</surname><given-names>TG</given-names></name><name name-style="western"><surname>Valdes</surname><given-names>F</given-names></name></person-group><article-title>Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis</article-title><source>Am J Kidney Dis</source><year>2002</year><volume>39</volume><fpage>337</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11840374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/ajkd.2002.30553</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annigeri</surname><given-names>R</given-names></name><name name-style="western"><surname>Conly</surname><given-names>J</given-names></name><name name-style="western"><surname>Vas</surname><given-names>S</given-names></name><name name-style="western"><surname>Dedier</surname><given-names>H</given-names></name><name name-style="western"><surname>Prakashan</surname><given-names>KP</given-names></name><name name-style="western"><surname>Bargman</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection</article-title><source>Perit Dial Int</source><year>2001</year><volume>21</volume><fpage>554</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11783763</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hwiesh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Abdul-Rahman</surname><given-names>IS</given-names></name><name name-style="western"><surname>Al-Muhanna</surname><given-names>FA</given-names></name><name name-style="western"><surname>Al-Sulaiman</surname><given-names>MH</given-names></name><name name-style="western"><surname>Al-Jondebi</surname><given-names>MS</given-names></name><name name-style="western"><surname>Divino-Filho</surname><given-names>JC</given-names></name></person-group><article-title>Prevention of peritoneal dialysis cath-eter infections in Saudi peritoneal dialysis patients: The emergence of high-level mupirocin resistance</article-title><source>Int J Artif Organs</source><year>2013</year><volume>36</volume><fpage>473</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">23897229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5301/ijao.5000207</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piraino</surname><given-names>B</given-names></name><name name-style="western"><surname>Bernardini</surname><given-names>J</given-names></name><name name-style="western"><surname>Florio</surname><given-names>T</given-names></name><name name-style="western"><surname>Fried</surname><given-names>L</given-names></name></person-group><article-title>Staphylococcus aureus prophylaxis and trends in gram negative infections in peritoneal dialysis patients</article-title><source>Perit Dial Int</source><year>2003</year><volume>23</volume><fpage>456</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14604197</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardini</surname><given-names>J</given-names></name><name name-style="western"><surname>Piraino</surname><given-names>B</given-names></name><name name-style="western"><surname>Holley</surname><given-names>J</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>JR</given-names></name><name name-style="western"><surname>Lutes</surname><given-names>R</given-names></name></person-group><article-title>A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampicin</article-title><source>Am J Kidney Dis</source><year>1996</year><volume>27</volume><fpage>695</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">8629630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(96)90105-5</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierce</surname><given-names>DA</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Mauck</surname><given-names>VS</given-names></name><name name-style="western"><surname>Russell</surname><given-names>GB</given-names></name><name name-style="western"><surname>Palavecino</surname><given-names>E</given-names></name><name name-style="western"><surname>Burkart</surname><given-names>JM</given-names></name></person-group><article-title>The effect on peritoneal dialysis pathogens of changing topical antibiotic prophylaxis</article-title><source>Perit Dial Int</source><year>2012</year><volume>32</volume><fpage>525</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">22302770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2011.00183</pub-id><pub-id pub-id-type="pmcid">PMC3524877</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>MW</given-names></name><name name-style="western"><surname>Mak</surname><given-names>SK</given-names></name><name name-style="western"><surname>Wong</surname><given-names>YY</given-names></name><name name-style="western"><surname>Lo</surname><given-names>KC</given-names></name><name name-style="western"><surname>Chan</surname><given-names>SF</given-names></name><name name-style="western"><surname>Tong</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Atypical mycobacterial exit site infection and peritonitis in peritoneal dialysis patients on prophylactic exit site gentamicin cream</article-title><source>Perit Dial Int</source><year>2013</year><volume>33</volume><fpage>267</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">23032088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2011.00184</pub-id><pub-id pub-id-type="pmcid">PMC3649895</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>KN</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>N</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>RK</given-names></name><name name-style="western"><surname>Verma</surname><given-names>AK</given-names></name><name name-style="western"><surname>Ayyagari</surname><given-names>A</given-names></name></person-group><article-title>Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: A single centre Indian experience</article-title><source>J Infect</source><year>2004</year><volume>48</volume><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">14667798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0163-4453(03)00119-1</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>AY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>AW</given-names></name><name name-style="western"><surname>Li</surname><given-names>PK</given-names></name><name name-style="western"><surname>Lam</surname><given-names>PK</given-names></name><name name-style="western"><surname>Leung</surname><given-names>CB</given-names></name><name name-style="western"><surname>Lai</surname><given-names>KN</given-names></name><etal/></person-group><article-title>Factors predicting outcome of fungal peritonitis in peritoneal dialysis: Analysis of a 9-year experience of fungal peritonitis in a single center</article-title><source>Am J Kidney Dis</source><year>2000</year><volume>36</volume><fpage>1183</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11096043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/ajkd.2000.19833</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldie</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kiernan-Troidle</surname><given-names>L</given-names></name><name name-style="western"><surname>Torres</surname><given-names>C</given-names></name><name name-style="western"><surname>Gorban-Brennan</surname><given-names>N</given-names></name><name name-style="western"><surname>Dunne</surname><given-names>D</given-names></name><name name-style="western"><surname>Kliger</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Fungal peritonitis in a large chronic peritoneal dialysis population: A report of 55 episodes</article-title><source>Am J Kidney Dis</source><year>1996</year><volume>28</volume><fpage>86</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">8712227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(96)90135-3</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>WK</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CY</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>SW</given-names></name><name name-style="western"><surname>Poon</surname><given-names>JF</given-names></name><name name-style="western"><surname>Chan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>IK</given-names></name></person-group><article-title>A prospective randomized control study of oral nystatin prophylaxis for Candida peri-tonitis complicating continuous ambulatory peritoneal dialysis</article-title><source>Am J Kidney Dis</source><year>1996</year><volume>28</volume><fpage>549</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">8840945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(96)90466-7</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Restrepo</surname><given-names>C</given-names></name><name name-style="western"><surname>Chacon</surname><given-names>J</given-names></name><name name-style="western"><surname>Manjarres</surname><given-names>G</given-names></name></person-group><article-title>Fungal peritonitis in peritoneal dialy-sis patients: Successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial</article-title><source>Perit Dial Int</source><year>2010</year><volume>30</volume><fpage>619</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">20634438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2008.00189</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rocklin</surname><given-names>MA</given-names></name><name name-style="western"><surname>Teitelbaum</surname><given-names>I</given-names></name></person-group><article-title>Noninfectious causes of cloudy peritoneal dialysate</article-title><source>Semin Dial</source><year>2001</year><volume>14</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11208038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1525-139x.2001.00012.x</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gould</surname><given-names>IM</given-names></name><name name-style="western"><surname>Casewell</surname><given-names>MW</given-names></name></person-group><article-title>The laboratory diagnosis of peritonitis during continuous ambulatory peritoneal dialysis</article-title><source>J Hosp Infect</source><year>1986</year><volume>7</volume><fpage>155</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">2871078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0195-6701(86)90058-7</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flanigan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>RM</given-names></name><name name-style="western"><surname>Lim</surname><given-names>VS</given-names></name></person-group><article-title>Cellular response to peritonitis among peritoneal dialysis patients</article-title><source>Am J Kidney Dis</source><year>1985</year><volume>6</volume><fpage>420</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">4073021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(85)80105-0</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Tak</surname><given-names>WT</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>Using reagent strips for rapid diagnosis of peritonitis in peritoneal dialysis patients</article-title><source>Adv Perit Dial</source><year>2005</year><volume>21</volume><fpage>69</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">16686288</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akman</surname><given-names>S</given-names></name><name name-style="western"><surname>Uygun</surname><given-names>V</given-names></name><name name-style="western"><surname>Guven</surname><given-names>AG</given-names></name></person-group><article-title>Value of the urine strip test in the early diagnosis of bacterial peritonitis</article-title><source>Pediatr Int</source><year>2005</year><volume>47</volume><fpage>523</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16190958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1442-200x.2005.02119.x</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen-Khac</surname><given-names>E</given-names></name><name name-style="western"><surname>Cadranel</surname><given-names>JF</given-names></name><name name-style="western"><surname>Thevenot</surname><given-names>T</given-names></name><name name-style="western"><surname>Nousbaum</surname><given-names>JB</given-names></name></person-group><article-title>Review article: The utility of reagent strips in the diagnosis of infected ascites in cirrhotic patients</article-title><source>Aliment Pharmacol Ther</source><year>2008</year><volume>28</volume><fpage>282</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19086234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2036.2008.03735.x</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>TH</given-names></name><name name-style="western"><surname>Chang</surname><given-names>KH</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>HY</given-names></name><name name-style="western"><surname>Park</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Usefulness of 23S rRNA amplification by PCR in the detection of bacteria in CAPD peritonitis</article-title><source>Am J Nephrol</source><year>2006</year><volume>26</volume><fpage>115</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16543715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000092040</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>G</given-names></name><name name-style="western"><surname>Wilks</surname><given-names>M</given-names></name><name name-style="western"><surname>Warwick</surname><given-names>S</given-names></name><name name-style="western"><surname>Millar</surname><given-names>MR</given-names></name><name name-style="western"><surname>Fan</surname><given-names>SL</given-names></name></person-group><article-title>Comparative study of diagnosis of PD peritonitis by quantitative polymerase chain reaction for bacterial DNA vs culture methods</article-title><source>J Nephrol</source><year>2006</year><volume>19</volume><fpage>45</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16523425</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ro</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hamada</surname><given-names>C</given-names></name><name name-style="western"><surname>Io</surname><given-names>H</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Hirahara</surname><given-names>I</given-names></name><name name-style="western"><surname>Tomino</surname><given-names>Y</given-names></name></person-group><article-title>Rapid, simple, and reliable method for the diagnosis of CAPD peritonitis using the new MMP-9 test kit</article-title><source>J Clin Lab Anal</source><year>2004</year><volume>18</volume><fpage>224</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15202114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcla.20027</pub-id><pub-id pub-id-type="pmcid">PMC6807828</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>K</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Iino</surname><given-names>N</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>G</given-names></name><name name-style="western"><surname>Shimotori</surname><given-names>M</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Rapid detection of causative pathogen of peritonitis using in-situ hybrid-ization in a patient with continuous ambulatory peritoneal dialysis</article-title><source>J Infect Chemother</source><year>2007</year><volume>13</volume><fpage>273</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17721693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10156-007-0531-x</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>HS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name><name name-style="western"><surname>Song</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Oh</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Evaluation of DNA extraction methods and their clinical application for direct detec-tion of causative bacteria in continuous ambulatory peritoneal dialysis culture fluids from patients with peritonitis by using broad-range PCR</article-title><source>Ann Lab Med</source><year>2012</year><volume>32</volume><fpage>119</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">22389878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3343/alm.2012.32.2.119</pub-id><pub-id pub-id-type="pmcid">PMC3289776</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>YT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>MC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>AB</given-names></name><name name-style="western"><surname>Sung</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sun</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Rapid identification of bacteria and Candida pathogens in peritoneal dialysis effluent from patients with peritoneal dialysis-related peritonitis by use of multilocus PCR coupled with electrospray ionization mass spectrom-etry</article-title><source>J Clin Microbiol</source><year>2014</year><volume>52</volume><fpage>1217</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24430451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JCM.03106-13</pub-id><pub-id pub-id-type="pmcid">PMC3993497</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadi</surname><given-names>SH</given-names></name><name name-style="western"><surname>Neela</surname><given-names>V</given-names></name><name name-style="western"><surname>Hamat</surname><given-names>RA</given-names></name><name name-style="western"><surname>Goh</surname><given-names>BL</given-names></name><name name-style="western"><surname>Syafinaz</surname><given-names>AN</given-names></name></person-group><article-title>Rapid detection and identification of pathogens in patients with continuous ambula-tory peritoneal dialysis (CAPD) associated peritonitis by 16s rRNA gene sequencing</article-title><source>Trop Biomed</source><year>2013</year><volume>30</volume><fpage>602</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24522129</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>CY</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>GW</given-names></name><name name-style="western"><surname>Kift-Morgan</surname><given-names>A</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>KL</given-names></name><name name-style="western"><surname>Topley</surname><given-names>N</given-names></name><name name-style="western"><surname>Eberl</surname><given-names>M</given-names></name></person-group><article-title>Pathogen-specific local immune fingerprints diagnose bacterial infec-tion in peritoneal dialysis patients</article-title><source>J Am Soc Nephrol</source><year>2013</year><volume>24</volume><fpage>2002</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24179164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2013040332</pub-id><pub-id pub-id-type="pmcid">PMC3839555</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bieber</surname><given-names>SD</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>AE</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>R</given-names></name></person-group><article-title>Diagnostic testing for peritonitis in patients undergoing peritoneal dialysis</article-title><source>Semin Dial</source><year>2014</year><volume>27</volume><fpage>602</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">25039456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/sdi.12270</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>N</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>KN</given-names></name></person-group><article-title>Isolation of bacterial DNA followed by sequencing and differing cytokine response in peritoneal dialysis effluent help in identifying bacteria in culture negative peritonitis</article-title><source>Nephrology</source><year>2018</year><volume>23</volume><fpage>148</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">27859980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nep.12969</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barretti</surname><given-names>P</given-names></name><name name-style="western"><surname>Doles</surname><given-names>JV</given-names></name><name name-style="western"><surname>Pinotti</surname><given-names>DG</given-names></name><name name-style="western"><surname>El Dib</surname><given-names>R</given-names></name></person-group><article-title>Efficacy of antibiotic therapy for peritoneal dialysis-associated peritonitis: A proportional meta-analysis</article-title><source>BMC Infect Dis</source><year>2014</year><volume>14</volume><fpage>445</fpage><pub-id pub-id-type="pmid">25135487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2334-14-445</pub-id><pub-id pub-id-type="pmcid">PMC4262222</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyce</surname><given-names>NW</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>NM</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>P</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>RC</given-names></name></person-group><article-title>Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis&#8212;A prospective, randomized comparison of intermittent v continuous therapy</article-title><source>Am J Kidney Dis</source><year>1988</year><volume>12</volume><fpage>304</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3177373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(88)80224-5</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>CL</given-names></name><name name-style="western"><surname>Bailie</surname><given-names>GR</given-names></name><name name-style="western"><surname>Evans</surname><given-names>A</given-names></name><name name-style="western"><surname>Eisele</surname><given-names>G</given-names></name><name name-style="western"><surname>Venezia</surname><given-names>RA</given-names></name></person-group><article-title>Pharmacokinetics of once-daily IP gentamicin in CAPD patients</article-title><source>Perit Dial Int</source><year>1996</year><volume>16</volume><fpage>379</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8863331</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>CL</given-names></name><name name-style="western"><surname>Gopalakrishna</surname><given-names>K</given-names></name><name name-style="western"><surname>Lye</surname><given-names>WC</given-names></name></person-group><article-title>Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients</article-title><source>J Am Soc Nephrol</source><year>2000</year><volume>11</volume><fpage>1117</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">10820176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.V1161117</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manley</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Bailie</surname><given-names>GR</given-names></name><name name-style="western"><surname>Frye</surname><given-names>RF</given-names></name><name name-style="western"><surname>McGoldrick</surname><given-names>MD</given-names></name></person-group><article-title>Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients</article-title><source>Perit Dial Int</source><year>2001</year><volume>21</volume><fpage>378</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">11587401</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manley</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Bailie</surname><given-names>GR</given-names></name><name name-style="western"><surname>Frye</surname><given-names>R</given-names></name><name name-style="western"><surname>McGoldrick</surname><given-names>MD</given-names></name></person-group><article-title>Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients</article-title><source>Perit Dial Int</source><year>2000</year><volume>20</volume><fpage>686</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">11216560</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fish</surname><given-names>R</given-names></name><name name-style="western"><surname>Nipah</surname><given-names>R</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C</given-names></name><name name-style="western"><surname>Finney</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>SL</given-names></name></person-group><article-title>Intraperitoneal vancomycin concentrations during peritoneal dialysis-associated peritonitis: Cor-relation with serum levels</article-title><source>Perit Dial Int</source><year>2012</year><volume>32</volume><fpage>332</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22045102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2010.00294</pub-id><pub-id pub-id-type="pmcid">PMC3525447</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevenson</surname><given-names>S</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mudge</surname><given-names>DW</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>CM</given-names></name><name name-style="western"><surname>Badve</surname><given-names>SV</given-names></name><etal/></person-group><article-title>The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis</article-title><source>Perit Dial Int</source><year>2015</year><volume>35</volume><fpage>222</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24584597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2013.00156</pub-id><pub-id pub-id-type="pmcid">PMC4406318</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blunden</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeitlin</surname><given-names>D</given-names></name><name name-style="western"><surname>Ashman</surname><given-names>N</given-names></name><name name-style="western"><surname>Fan</surname><given-names>SL</given-names></name></person-group><article-title>Single UK centre experience on the treatment of PD peritonitis&#8212;antibiotic levels and outcomes</article-title><source>Nephrol Dial Transplant</source><year>2007</year><volume>22</volume><fpage>1714</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17369615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfm079</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulhern</surname><given-names>JG</given-names></name><name name-style="western"><surname>Braden</surname><given-names>GL</given-names></name><name name-style="western"><surname>O'Shea</surname><given-names>MH</given-names></name><name name-style="western"><surname>Madden</surname><given-names>RL</given-names></name><name name-style="western"><surname>Lipkowitz</surname><given-names>GS</given-names></name><name name-style="western"><surname>Germain</surname><given-names>MJ</given-names></name></person-group><article-title>Trough serum vancomycin levels predict the relapse of Gram-positive peritonitis in peritoneal dialysis patients</article-title><source>Am J Kidney Dis</source><year>1995</year><volume>25</volume><fpage>611</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7702059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0272-6386(95)90132-9</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>DW</given-names></name></person-group><article-title>Do antibiotic levels need to be followed in treating peri-toneal dialysis-associated peritonitis?</article-title><source>Semin Dial</source><year>2011</year><volume>24</volume><fpage>445</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21801204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1525-139X.2011.00883.x</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>P</given-names></name><name name-style="western"><surname>Nemati</surname><given-names>E</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></name><name name-style="western"><surname>Preston</surname><given-names>E</given-names></name><name name-style="western"><surname>Levy</surname><given-names>J</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E</given-names></name></person-group><article-title>Peritoneal dialysis catheter removal for acute peritonitis: A retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>43</volume><fpage>103</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">14712433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2003.08.046</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>A</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bargman</surname><given-names>JM</given-names></name></person-group><article-title>Streptococcal PD peritonitis&#8212;A 10-year review of one centre's experience</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><fpage>3545</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17005523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfl407</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>DY</given-names></name><name name-style="western"><surname>To</surname><given-names>KK</given-names></name><name name-style="western"><surname>Yip</surname><given-names>TP</given-names></name><name name-style="western"><surname>Lui</surname><given-names>SL</given-names></name><name name-style="western"><surname>Chan</surname><given-names>TM</given-names></name><name name-style="western"><surname>Lai</surname><given-names>KN</given-names></name><etal/></person-group><article-title>Streptococcus bovis peritonitis complicating peritoneal dialysis&#8211;A review of 10 years' experience</article-title><source>Perit Dial Int</source><year>2012</year><volume>32</volume><fpage>55</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21804137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2010.00304</pub-id><pub-id pub-id-type="pmcid">PMC3525383</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szeto</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chow</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kwan</surname><given-names>BC</given-names></name><name name-style="western"><surname>Law</surname><given-names>MC</given-names></name><name name-style="western"><surname>Chung</surname><given-names>KY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Staphylo-coccus aureus peritonitis complicates peritoneal dialysis: Review of 245 consecutive cases</article-title><source>Clin J Am Soc Nephrol</source><year>2007</year><volume>2</volume><fpage>245</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17699420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.03180906</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Govindarajulu</surname><given-names>S</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>CM</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>SP</given-names></name><name name-style="western"><surname>Brown</surname><given-names>FG</given-names></name><name name-style="western"><surname>Rosman</surname><given-names>JB</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: Predictors, treatment and outcomes in 503 cases</article-title><source>Perit Dial Int</source><year>2010</year><volume>30</volume><fpage>311</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20190031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2008.00258</pub-id></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siva</surname><given-names>B</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>CM</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>SP</given-names></name><name name-style="western"><surname>Brown</surname><given-names>FG</given-names></name><name name-style="western"><surname>Rosman</surname><given-names>JB</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Pseudomonas peritonitis in Australia: Predictors, treatment, and outcomes in 191 cases</article-title><source>Clin J Am Soc Nephrol</source><year>2009</year><volume>4</volume><fpage>957</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19406972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.00010109</pub-id><pub-id pub-id-type="pmcid">PMC2676190</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzanetou</surname><given-names>K</given-names></name><name name-style="western"><surname>Triantaphilis</surname><given-names>G</given-names></name><name name-style="western"><surname>Tsoutsos</surname><given-names>D</given-names></name><name name-style="western"><surname>Petropoulou</surname><given-names>D</given-names></name><name name-style="western"><surname>Ganteris</surname><given-names>G</given-names></name><name name-style="western"><surname>Malamou-Lada</surname><given-names>E</given-names></name><etal/></person-group><article-title>Strenotophomonas maltophila peritonitis in CAPD patients: Susceptibility of antibioticis and treatment outcome: A report of five cases</article-title><source>Perit Dial Int</source><year>2004</year><volume>24</volume><fpage>401</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15335157</pub-id></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bunke</surname><given-names>M</given-names></name><name name-style="western"><surname>Brier</surname><given-names>ME</given-names></name><name name-style="western"><surname>Golper</surname><given-names>TA</given-names></name></person-group><article-title>Culture-negative CAPD peritonitis: The Network 9 Study</article-title><source>Adv Perit Dial</source><year>1994</year><volume>10</volume><fpage>174</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7999821</pub-id></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fahim</surname><given-names>M</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>CM</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>SP</given-names></name><name name-style="western"><surname>Brown</surname><given-names>FG</given-names></name><name name-style="western"><surname>Rosman</surname><given-names>JB</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Culture-negative peritonitis in peritoneal dialysis patients in Australia: Predictors, treatment and outcomes in 435 cases</article-title><source>Am J Kidney Dis</source><year>2010</year><volume>55</volume><fpage>690</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20110144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2009.11.015</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szeto</surname><given-names>CC</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TY</given-names></name><name name-style="western"><surname>Chow</surname><given-names>KM</given-names></name><name name-style="western"><surname>Leung</surname><given-names>CB</given-names></name><name name-style="western"><surname>Li</surname><given-names>PK</given-names></name></person-group><article-title>The clinical course of culture-negative peritonitis complicating peritoneal dialysis</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>42</volume><fpage>567</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">12955686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0272-6386(03)00790-x</pub-id></element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miles</surname><given-names>R</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>CM</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>SP</given-names></name><name name-style="western"><surname>Brown</surname><given-names>FG</given-names></name><name name-style="western"><surname>Rosman</surname><given-names>JB</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients</article-title><source>Kidney Int</source><year>2009</year><volume>76</volume><fpage>622</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19516241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2009.202</pub-id></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matuszkiewicz-Rowinska</surname><given-names>J</given-names></name></person-group><article-title>Update on fungal peritonitis and its treat-ment</article-title><source>Perit Dial Int</source><year>2009</year><volume>29</volume><issue>Suppl 2</issue><fpage>S161</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19270208</pub-id></element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadeau-Fredette</surname><given-names>AC</given-names></name><name name-style="western"><surname>Bargman</surname><given-names>JM</given-names></name></person-group><article-title>Characteristics and outcomes of fungal peritonitis in a modern North American cohort</article-title><source>Perit Dial Int</source><year>2015</year><volume>35</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">24497586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2013.00179</pub-id><pub-id pub-id-type="pmcid">PMC4335931</pub-id></element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basturk</surname><given-names>T</given-names></name><name name-style="western"><surname>Koc</surname><given-names>Y</given-names></name><name name-style="western"><surname>Unsal</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahbap</surname><given-names>E</given-names></name><name name-style="western"><surname>Sakaci</surname><given-names>T</given-names></name><name name-style="western"><surname>Yildiz</surname><given-names>I</given-names></name><etal/></person-group><article-title>Fungal peri-tonitis in peritoneal dialysis: A 10-year retrospective analysis in a single center</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2012</year><volume>16</volume><fpage>1696</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">23161042</pub-id></element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>KM</given-names></name><name name-style="western"><surname>Chow</surname><given-names>VC</given-names></name><name name-style="western"><surname>Hung</surname><given-names>LC</given-names></name><name name-style="western"><surname>Wong</surname><given-names>SM</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>CC</given-names></name></person-group><article-title>Tuberculous peritonitis-associated mortality is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples</article-title><source>Clin Infect Dis</source><year>2002</year><volume>35</volume><fpage>409</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12145724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/341898</pub-id></element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>H</given-names></name><name name-style="western"><surname>Washida</surname><given-names>N</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Shinozuka</surname><given-names>K</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>T</given-names></name><name name-style="western"><surname>Uchiyama</surname><given-names>K</given-names></name><etal/></person-group><article-title>Non-tuberculous mycobacterial infections related to peritoneal dialysis</article-title><source>Perit Dial Int</source><year>2018</year><volume>38</volume><fpage>147</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">29563276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3747/pdi.2017.00172</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>